An Open Label Phase 2 Study to Evaluate the Safety and Efficacy of Lenvatinib With Pembrolizumab or Lenvatinib, Pembrolizumab and FLOT in the Neoadjuvant / Adjuvant Treatment for Patients With Gastric Cancer
National Cancer Center Hospital East
National Cancer Center Hospital East
Astellas Pharma Inc
Amgen
ImmunityBio, Inc.
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
The Netherlands Cancer Institute
OncoC4, Inc.
Australasian Gastro-Intestinal Trials Group
The Netherlands Cancer Institute